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ABSTRACT:
  Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group 
of tumors with variable presentation and clinical behavior. Despite improvements in 
surgical and radiation therapy techniques, the 5-year survival rate has not improved 
significantly over the past decades. Thus, there is an urgent need to identify novel 
markers that may allow for the development of personalized therapeutic approaches. 
In the present study we evaluated the prognostic role of the expression of 
genes related to the induction of epithelial mesenchymal transition (EMT). To 
this aim, a consecutive series of 69 HNSCC were analyzed for the expression 
of TWIST1, TWIST2, SNAI1, SNAI2, E-Cadherin, N-Cadherin and Vimentin.
  TWIST1,  TWIST2,  SNAI1  and  SNAI2  were  significantly  overexpressed 
in HNSCC, with TWIST2, SNAI1 and SNAI2 being more markedly increased in 
tumors compared to normal mucosae. The expression of TWIST1 and SNAI2 
was associated with upregulation of mesenchymal markers, but failed to 
correlate with pathological parameters or clinical behaviour. In contrast, we 
found that upregulation of TWIST2, which was independent of the activation 
of a mesenchymal differentiation program, correlated with poor differentiation 
grade (p=0.016) and shorter survival (p=0.025), and identifies a subset of node-
positive oral cavity/pharynx cancer patients with very poor prognosis (p<0.001). 
  Overall our study suggests that the assessment of TWIST2 
expression might help to stratify HNSCC patients for risk of disease 
progression, pointing to TWIST2 as a potential prognostic marker.
INTRODUCTION
Head and neck squamous cell carcinomas 
(HNSCCs), which include malignancies originating from 
oral cavity, pharynx and larynx, are a heterogeneous 
group of tumors with variable presentation and biological 
behavior. The estimated worldwide incidence is about 
500,000 new cases per year [1], with over 63,000 events/
year in Europe [2]. 
Although HNSCC is highly curable when diagnosed 
at early stage, the majority of patients present at the 
diagnosis with loco-regionally advanced disease (stage 
III-IV), which results in poor prognosis. In fact, despite 
improvements in surgical and radiation therapies, still 
HNSCC remains a cancer associated with a high mortality 
rate. The recent integration of systemic chemotherapeutic Oncotarget 2011; 2:   1165 - 1175 1166 www.impactjournals.com/oncotarget
therapy has slightly improved survival but the toxic effects 
are not negligible [3-5]. Unfortunately, conventional 
staging parameters, such as site and size of the tumor, 
lymph node involvement or presence of distant metastases 
(TNM), fail to provide a clear-cut risk stratification, which 
prevents the development of personalized approaches. 
Thus, there is an urgent need for the identification of new 
and more reliable diagnostic/prognostic markers and the 
validation of novel therapeutic targets.
Recent studies indicate that the phenomenon of 
epithelial-mesenchymal transition (EMT) plays a key role 
in carcinoma aggressiveness. EMT is a process whereby 
a cell loses the epithelial constraints of cell-cell and cell-
extracellular matrix interactions, undergoes cytoskeleton 
reorganization and gains a mesenchymal phenotype. This 
is accompanied by a reprogramming of the transcriptional 
machinery that results in de novo activation of 
mesenchymal markers, such as N-Cadherin and Vimentin, 
and loss of epithelial intercellular adhesion molecules, 
such as E-Cadherin [6]. Essential for the development 
of embryonic mesoderm [7, 8], EMT is potentially 
destructive if deregulated, and it is becoming increasingly 
clear that inappropriate utilization of EMT mechanisms is 
an integral component of malignant progression of several 
epithelial tumors [9]. Two classes of transcription factors, 
including the TWIST proteins TWIST1 and TWIST2 and 
the SNAI proteins SNAI1 and SNAI2 play a pivotal role 
in the induction of EMT. Neo activation of these genes, 
that are essentially silent in normal epithelial tissues, has 
been reported to correlate with EMT in several types of 
cancer, including breast, colon, stomach, thyroid, and 
hepatocellular carcinomas [10-17]. Aberrant expression 
of these transcription factors has been associated also 
with the bypass of oncogene-induced failsafe programs 
Figure 1: Box-and-whiskers plot representing relative expression levels of EMT-related genes in HNSCC (T) and 
normal mucosae (N). Gene expression levels are shown on the ordinate (log scale). The upper and lower horizontal lines of the box 
correspond to the first and third quartiles, the middle horizontal line the median, the whiskers maximum and minimum values. Wilcoxon-
Mann-Whitney test was used to compare median values in normal and tumor samples.
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(apoptosis and premature senescence) and drug resistance, 
suggesting that TWIST and SNAIL proteins may impinge 
upon pathways that are both dependent and independent 
of transdifferentiation [18-26].
Based on this body of information, we sought to 
investigate the role of EMT molecules TWIST1, TWIST2, 
SNAI1 and SNAI2 in HNSCC development and assess 
their potential diagnostic/prognostic value. 
RESULTS
Gene expression
Demographic, clinical and pathological features of 
the 69 HNSCC cases analyzed in this study are shown in 
Table 1. 
Expression levels of the mRNA encoding TWIST1, 
TWIST2, SNAI1, SNAI2, N-Cadherin and Vimentin were 
all significantly increased in tumors compared to healthy 
mucosa, with TWIST2, SNAI1 and SNAI2 displaying the 
greatest increments (Figure 1). In particular, the extent of 
the increase, calculated as the ratio of the median value 
detected in tumors vs the median value detected in normal 
mucosae, was 3.8 fold for TWIST1, 20.9 for TWIST2, 
23.4 for SNAI1, 29.5 for SNAI2, 5.2 for N-Cadherin 
and 6.3 fold for Vimentin. A trend toward reduction of 
E-cadherin mRNA expression in tumors compared to 
normal tissues could be observed, although it was not 
statistically significant.
EMT is conventionally described as a coordinate 
activation of mesenchymal markers (e.g. Vimentin and 
N-cadherin) and loss of expression of epithelial markers 
(e.g. E-cadherin). The activation of either TWIST1, 
TWIST2, SNAI1, SNAI2 resulted in a negligible 
downregulation of E-cadherin, while TWIST1 and 
SNAI2 displayed a good correlation with the expression 
of Vimentin and N-cadherin (Table 2). These latter were 
also positively correlated one to the other. In contrast, 
SNAI1 and TWIST2, which were reciprocally correlated, 
were independent of the activation of mesenchymal 
markers (Vimentin and N-cadherin) (Table 2). The lack of 
correlation between TWIST2 and induction of a canonical 
EMT phenotype was confirmed also at the protein level 
(Figure 2).
To better assess the role of these genes in HNSCC 
and to corroborate our results, a systematic analysis 
Characteristic n (%)
Gender
Male 65 94.2
Female 4 5.8
Age
<60 41 59.4
≥60 28 40.6
Anatomic site
Tongue 17 24.6
Oral cavity 3 4.3
Oropharynx 13 18.8
Hypopharynx 20 29.0
Larynx 16 23.2
pT status
1 6 8.7
2 15 21.7
3 20 29.0
4 28 40.6
pN status
0 20 29.0
1 5 7.2
2b 18 26.1
2c 23 33.3
3 2 2.9
X (unknown) 1 1.4
Histological grading
Well differentiated 2 2.9
Moderately differentiated 37 53.6
Poorly differentiated 30 43.5
Stage
I 4 5.8
II 5 7.2
III 10 14.5
IV 50 72.5
Table 1: Demographic and clinical-pathological characteristics of HNSCC patients.Oncotarget 2011; 2:   1165 - 1175 1168 www.impactjournals.com/oncotarget
of 11 gene expression datasets available in Oncomine 
and in EBI Array Express databases was carried out. 
The various pro-EMT transcription factors (TWIST1, 
TWIST2, SNAI1 and SNAI2) displayed different degrees 
of reciprocal interdependence in different datasets. In 
particular, in most datasets TWIST1 and SNAI2 were 
reciprocally correlated, as well as the expression of 
Vimentin and N-cadherin, which is in agreement with our 
data. Moreover, the co-upregulation of these mesenchymal 
markers (Pearson’s correlation coefficient r > 0.2) was 
associated to a significant downregulation of E-cadherin (r 
< -0.2) in only 3 out of 11 datasets (Supplementary Table 
1), indicating that de novo gain of mesenchymal features 
may coexist with the expression of epithelial markers in 
a relevant proportion of HNSCC. The analysis supported 
also the role of TWIST1 and SNAI2 in the induction of 
an EMT program in HNSCC. In fact, the overexpression 
of Vimentin and N-cadherin was associated to the 
upregulation of TWIST1 in 7 out of 11 datasets and of 
SNAI2 in 6 out of 11 datasets. Similar to what observed 
in our series, TWIST2 expression failed to correlate with 
Vimentin and N-cadherin in the majority of datasets 
including this probe set, corroborating our observation 
of a marginal role for this TWIST family member in the 
induction of EMT in HNSCC. 
Having collected evidence that, different from 
TWIST1, TWIST2 does not correlate with gain of 
mesenchymal features, we sought to corroborate this 
observation by in vitro experiments. To this end, we 
ectopically expressed TWIST1 and TWIST2 in FADU 
cells, that are reported to be susceptible to EMT [27]. 
Different from TWIST1, ectopic expression of TWIST2 
failed to result in significant transcriptional modulation of 
EMT markers, thus supporting the concept that TWIST2 
is not involved in the promotion of EMT in the context of 
HNSCC (Supplementary Figure 1).
E-Cadherin N-Cadherin Vimentin  SNAI1 SNAI2 TWIST1 TWIST2
E-Cadherin  1 0 0 -0.1 -0.1 -0.1 -0.1
N-Cadherin 1 0.7 0.1 0.3 0.5 -0.1
Vimentin 1 0.1 0.7 0.6 0.1
SNAI1 1 0.1 0.1 0.6
SNAI2 1 0.5 0.1
TWIST1 1 0
TWIST2 1
0.2 < r < 0.3 weak association 0.3 ≤ r < 0.5 moderate association r  ≥ 0.5 strong association
Table 2: Expression of EMT-associated genes in HNSCC: Pearson’s correlation coefficients (all tumor sites)
Figure 2: Immunohistochemical staining of a hypopharyngeal squamous cell carcinoma with high TWIST2 expression 
not associated to EMT. The tumor displays a strong TWIST2 reactivity (A) accompanied by E-cadherin expression (B) and is negative 
for Vimentin (C) and N-cadherin (D). Magnification 200x.Oncotarget 2011; 2:   1165 - 1175 1169 www.impactjournals.com/oncotarget
Pathological correlations
No  significant  associations  between  TWIST1, 
TWIST2, SNAI1, SNAI2, E-Cadherin, N-Cadherin or 
Vimentin and patient’s age, gender, tumor site, size, 
nodal status or staging were found (Supplementary Table 
2). Instead, a positive correlation between TWIST2 
expression and histopathological differentiation grade 
was  detected:  TWIST2  was  significantly  increased  in 
poorly differentiated HNSCC, as compared to well/
moderately differentiated tumors (p=0.02, Wilcoxon-
Mann-Whitney test ). The positive association between 
TWIST2 and histopathological grading was also 
confirmed by categorization of tumors into high and low 
gene expressors, considering the median as a cutoff value 
(p=0.016, Fisher exact test, Supplementary Table 2). 
Clinical correlations
As a preliminary step to the evaluation of the 
role of EMT in patient survival, we first assessed how 
conventional clinical-pathological parameters performed 
in our tumor series. In agreement with the literature, 
survival rates at 5 years where higher for larynx compared 
to oral cavity/pharynx cancer patients (tongue, oral cavity, 
oropharynx, hypopharynx). Moreover, positive nodal 
status, advanced tumor stage, and poor histopathological 
differentiation grade correlated with worse prognosis 
(Supplementary Table 3).
To assess the prognostic value of EMT-related genes, 
tumors were categorized according to their relative gene 
expression levels into high and low expressors, using the 
median as a cutoff value. We found that high expression 
levels  of  TWIST2  significantly  correlated  with  shorter 
survival in oral cavity/pharynx cancer patients, even after 
adjustment for tumor grading (Table 3 and Figure 3). No 
Figure 3: Kaplan-Meier estimates of overall survival (left panel) and cancer-specific survival (right panel) in oral 
cavity/pharynx cancer patients according to nodal status (A, D), TWIST2 expression (B, E) and combined nodal status 
and TWIST2 expression (C, F). White dots represent censored subjects.Oncotarget 2011; 2:   1165 - 1175 1170 www.impactjournals.com/oncotarget
significant correlation was observed for larynx cancers but 
the limited number of node-positive laryngeal neoplasms 
included in our series (5 cases) prevented us from drawing 
any  definitive  conclusion  about  the  significance  of 
TWIST2 in this tumor context (Supplementary Table 3). 
More interestingly, TWIST2 demonstrated a remarkable 
prognostic value when combined with patient’s nodal 
status. In fact, node-positive tumors overexpressing 
TWIST2 (node-positive/TWIST2-high) displayed a 
significant  poorer  outcome  compared  to  node-positive 
tumors expressing low levels of the gene (node-positive/
TWIST2-low) (Figure 3). Thus, TWIST2 expression 
identifies  a  group  of  node-positive  oral  cavity/pharynx 
cancer patients highly prone to progression.
Of the 11 datasets previously analyzed, only the 
dataset by Chung and coworkers included both TWIST2 
probesets and cancer-specific survival data (dataset XI, 
Supplementary Table 1) [28]. Similar to our result, also 
in Chung’s dataset high expression levels of TWIST2 
correlated with shorter survival, although, possibly 
because of the limited size of the series (28 cases), 
the  differences  failed  to  reach  statistical  significance 
(Supplementary Figure 2).
DISCUSSION
The much unexplained variability in the biological 
behaviour and clinical course is one of the major 
factors that hamper implementation of optimised risk-
adjusted therapeutic strategies for HNSCC [3, 4]. Recent 
studies indicate that the activation of an EMT program 
in  carcinomas  may  significantly  contribute  to  tumor 
progression [9-16]. On this basis we sought to investigate 
the role of EMT-related molecules in HNSCC development 
and aggressiveness.
Our study provides evidence that both the EMT 
transcription factors (TWIST1, TWIST2, SNAI1 and 
Overall Survival
Gene Expression 
levels§
n 5-years survival probability  Log-rank test HR (95% CI)
†
TWIST1
Low 27 29% 1
‡
High 26 46% p=0.168 0.62 (0.31-1.24)
TWIST2
Low 26 49% 1
High 27 26% p=0.025 2.18 (1.08-4.41)
SNAI1
Low 27 49% 1
High 26 26% p=0.519 1.32 (0.64-2.72) 
SNAI2
Low 27 33% 1
High 25 44% p=0.306 0.71 (0.35-1.44)
E-Cadherin
Low 29 34% 1
High 23 39% p=0.882 1.06 (0.53-2.13)
N-Cadherin
Low 27 37% 1
High 22 41% p=0.878 0.95 (0.46-1.98)
Vimentin
Low 26 34% 1
High 26 42% p=0.541 0.83 (0.41-1.68)
§ Expression levels equal/below (Low) or over (High) the median value.
† Estimated by means of Cox hazard. 
‡ Reference category.
Table 3: Kaplan-Meier estimates, hazard ratio of death (HR) and corresponding 95% confidence intervals (CI) 
according to gene expression levels in oral cavity/pharynx tumors.Oncotarget 2011; 2:   1165 - 1175 1171 www.impactjournals.com/oncotarget
SNAI2) and EMT markers (Vimentin and N-cadherin) 
are upregulated in a significant fraction of HNSCC, as 
compared to normal mucosa. TWIST1 and SNAI2 were 
reciprocally correlated, which is in line with recent 
evidence indicating that SNAI2 is a transcriptional target 
for TWIST1 [29]. Moreover, the expression of TWIST1 
and SNAI2 was positively correlated with the co-
activation of Vimentin and N-cadherin, in agreement with 
the reported role of EMT drivers for these transcription 
factors [9, 12, 14]. Overall, these data suggest that the 
initiation of a mesenchymal transition program involves 
a significant fraction of HNSCC. 
A systematic analysis of a series of 11 publicly 
available  transcriptional  profiling  HNSCC  datasets 
corroborated the concept that TWIST1 and SNAI2 are 
likely key regulators of EMT in these tumors. In fact, in 
the majority of the datasets analyzed the expression of 
either TWIST1 or SNAI2 was associated with the co-
activation of Vimentin and N-cadherin. In these data sets 
the co-upregulation of these mesenchymal markers did not 
necessarily associate with loss of E-cadherin expression, 
which is in line with our results and with recent findings by 
Nguyen and coworkers [30]. This suggests that in HNSCC 
the activation of a mesenchymal switch may be at least 
in part uncoupled from transcriptional downregulation 
of E-cadherin. Analogous observation has been recently 
reported also for non-small cell lung cancer [31].
Although the expression of TWIST1 and SNAI2 
correlated with the co-activation of Vimentin and 
N-cadherin and hence with the initiation of a mesenchymal 
differentiation program, in our tumor series they failed 
to  correlate  significantly  with  clinical-pathological 
characteristics. A positive correlation between TWIST 
protein expression and poor prognosis in HNSCC has 
been recently suggested by Ou and coworkers [32]. 
However, the antibody used by these authors recognizes 
both members of the TWIST family, which prevented 
the actual assessment of the specific role of TWIST1 and 
TWIST2 in this phenomenon. We provide evidence that 
both genes are involved in HNSCC, but TWIST2 is more 
markedly overexpressed compared to TWIST1 (median 
fold-increase: 20.9 for TWIST2, 3.8 for TWIST1). More 
importantly, we demonstrate that TWIST2 correlates with 
high tumor grade and short survival in oral cavity/pharynx 
cancer  patients  and  identifies,  within  the  N-positive 
category, a subset with high risk of progression. A 
correlation between TWIST2 expression levels and worse 
prognosis has been recently suggested for tongue [33] and 
salivary adenoid cystic carcinomas [34] and a similar trend 
could be observed also in the HNSCC series analyzed by 
Chung et al. [28].
Intriguingly, the expression of TWIST2 failed 
to correlate with the activation of a mesenchymal 
transition program (Vimentin/N-Cadherin upregulation 
and  E-cadherin  downregulation),  as  confirmed  both 
at transcriptional and protein level. This suggests that 
TWIST2 likely contributes to HNSCC aggressiveness via 
a mechanism different from the simple reprogramming of 
differentiation. In particular, the association of TWIST2 
expression  with  grading  and  survival  might  reflect  the 
ability of this gene to inhibit cellular safeguard programs, 
promote “stemness” and affect inflammatory response. In 
fact, TWIST2 has been reported to participate to stem cell 
renewal [35-38], to antagonize stress-induced apoptosis 
and to prevent oncogene-induced failsafe programs by 
interfering with both p53 and RB pathways [18, 20, 23, 39]. 
Moreover, elevated protein levels have been associated 
to aberrant proliferation and chromosome instability 
[21, 40] and, accordingly, we found that TWIST2 is 
overexpressed in high grade tumors that are characterized 
by elevated mitotic index, nuclear pleomorphisms and 
atypical mitoses. Finally, TWIST2 has been shown to 
negatively modulate the NF-kB-mediated production 
of  pro-inflammatory  cytokines  and  therefore  to  affect 
the immune response [41, 42]. Thus, TWIST2 could 
contribute to the poor prognosis of HNSCC by impinging 
on different pathways.
It should be pointed out that there is likely an overall 
underestimation of the role of TWIST2 in cancer. This is 
in part due to the fact that only very recently TWIST2-
specific antibodies have been made available and in part 
to the limited number of transcriptional arrays including 
TWIST2-specific probes. In fact, TWIST2 gene has been 
only  recently  properly  annotated  and  TWIST2-specific 
probes were included in commercially available arrays 
only since 2004 (Affymetrix U133 Plus 2.0).
Overall our data indicate that the gain of 
mesenchymal features seems to impact marginally on the 
clinical behavior of HNSCC. Rather, our study suggests 
that the assessment of TWIST2 expression, particularly 
in node-positive oral cavity/pharynx tumors, might help 
in identifying those cases that are at higher risk of fatal 
progression, pointing to TWIST2 as a potential marker. 
Although our study was performed on a limited number 
of cases, we consider that our results are worthy of further 
investigations and, if confirmed in a larger series, may 
provide novel criteria for risk stratification and disclose 
original therapeutic avenues for HNSCC patients.
MATERIALS AND METHODS
Tumors and patients
Sixty-nine patients with primary HNSCC undergoing 
surgery at the Unit of Otorhinolaryngology of the 
Pordenone City Hospital (North-East Italy) were enrolled in 
this study, prior approval of the institutional review board. 
No patient had received chemotherapy or radiotherapy 
treatment prior to surgery. Samples, readily collected after 
surgical resection, were histologically inspected by the Oncotarget 2011; 2:   1165 - 1175 1172 www.impactjournals.com/oncotarget
pathologist, dissected with a scalpel blade, snap-frozen in 
liquid nitrogen and then stored at –80°C until use. Before 
RNA extraction a section representative of the frozen 
sample was evaluated under the microscope to ascertain 
the high representation in tumor cells. As a control, 14 
samples of matching healthy mucosa, dissected free of 
non mucosal tissues, were also evaluated. Demographic, 
clinical and pathological features are shown in Table 1. 
Most patients were males (65 males, 4 females) with 
loco-regionally advanced disease (stage III–IV). Tumors 
included 53 oral cavity/pharynx tumors (17 tongue, ICD-
9 141; 3 oral cavity, ICD-9 144; 13 oropharynx, ICD-9 
146; 20 hypopharynx, ICD-9 148), and 16 larynx tumors 
(ICD-9 161). Histopathological classification and staging 
were  based  on  the  WHO  classification  and  on  UICC/
TNM system [43]. Information on survival was obtained 
through an active follow-up based on verification of vital 
status of patients. Median follow up was 45 months. 
Purification of RNA and c-DNA synthesis
Frozen tissues were dismembered with a TissueLyser 
(Retsch). Total RNA was extracted by the EZ1 RNA 
universal tissue kit on the EZ1 biorobot (QIAGEN) and 
treated with DNAse to eliminate DNA contamination. 
c-DNA was synthesized starting from 1 microgram 
of RNA by the Superscript III reverse transcriptase 
(Invitrogen), according to manufacturer’s protocol.
Quantitative real-time PCR
The relative expression of TWIST1, TWIST2, 
SNAI1, SNAI2, E-Cadherin, N-Cadherin, Vimentin was 
quantified by real-time RT-PCR the using the SYBR 
green PCR master mix and the ABI7900HT Sequence 
Detection System (Applied Biosystems). Transcript levels 
were normalized against GAPDH using the standard curve 
method  for  quantification,  and  expressed  in  arbitrary 
units relatively to a calibrator. For each gene, relative 
expression was obtained by dividing expression values by 
the median of normal samples. All results are means of 
three technical replicates. All data were confirmed on at 
least two independent RT-PCR reactions and, in 12 cases, 
also on two independent RNA extractions.
The following primers were used: 
TWIST1 (Ref. Seq. NG_008114.1), TWIST1-F: 
TCCTCTACCAGGTCCTCCA; TWIST1-R: 
GGAAACAATGACATCTAGGTCTC;  
TWIST2 (Ref. Seq. NM_057179.1), TWIST2-F: 
AGCGACGAGATGGACAATAAGATGACC; 
TWIST2-R: CGGTCCGGAGGTGGGTGGCG; 
E-Cadherin (CDH1) (Ref. Seq. NM_004360), 
CDH1-F: AAGGAGGCGGAGAAGAGGAC 
CDH1-R: CGTCGTTACGAGTCACTTCAGG; 
N-Cadherin (CDH2) (Ref. Seq. NM_001792.3), 
CDH2-F: GGTGGAGGAGAAGACCAG, 
CDH2R-R: GGCATCAGGCTCCACAGT; 
SNAI2 (Ref. Seq. NM_003068.3), SNAI2-F: 
ACATTAGAACTCACACGGGGA; SNAI2-R: 
GTGTGCTACACAGCAGCCAGA; SNAI1 
(Ref. Seq. NM_005985.2), SNAI1-F: 
CTGCAGGACTCTAATCCAGAGTT  
SNAI1-R: CGGTGGGGTTGAGGATCT; 
Vimentin (VIM), (Ref. Seq. NM_003380.3) 
VIM-F: ACAACCTGGCCGAGGACATC, 
VIM-R: AGAGACGCATTGTCAACATCCTG; 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), (Ref. Seq. NM_002046.3) GAPDH-F: 
CGGGAAGCTTGTGATCAATGG, GAPDH-R: 
GGCAGTGATGGCATGGACTG. 
PCR conditions were as follows: 95°C for 10 min, 
95°C for 15 sec, 55-63°C for 1 min for 40 cycles. 
Immunohistochemistry
Five µm sections were immunostained with an anti-
Twist2 polyclonal serum (AF 6249, R&D systems) which 
was first validated for absence of cross-reactivity against 
Twist1 on ectopically expressed human Twist1 and 
Twist2. Sections were also stained for E-cadherin (clone 
36B5,Novocastra, 1:100), N-cadherin (clone IAR06, 
Novocastra, 1:400) and Vimentin (clone V9, Dako, 1:400). 
Staining procedures were performed by an automated 
immunostainer (Bond System, Leica Microsystems) using 
a  non-biotin  detection  system  (Bond  Polymer  Refine, 
Leica Microsystems) and diaminobenzidine development. 
Heat-induced antigen retrieval was performed using Tris-
EDTA buffer (pH 9.0) in a water bath at 95°C for 30 min.
Transfections
FADU, a cell lines derived from a squamous cell 
carcinoma of the hypopharynx, was purchased from 
ATCC. Cells were transfected by the calcium-phosphate 
method with either myc-tagged TWIST1, TWIST2 or 
control pCDNA3 empty vector. Seventy-two hours 
following transfections, cells were harvested and analyzed 
by western blot for protein expression using the following 
antibodies: mouse monoclonal anti-myc tag (clone 9E10, 
Calbiochem); anti-Twist1 (clone 2C1a, Santacruz), anti-
E-cadherin (36/E-Cadherin, BD Biosciences), anti-N-
cadherin (clone 32, BD Biosciences), anti-GAPDH (clone 
6C5, Millipore) and rabbit polyclonal antibody anti-
Twist2 (AF 6249, R&D Systems).
Statistical analysis 
Wilcoxon-Mann-Whitney and Fisher’s exact tests 
were used to compare gene expression levels in tumors Oncotarget 2011; 2:   1165 - 1175 1173 www.impactjournals.com/oncotarget
and normal mucosae and to investigate the association 
with clinical-pathological parameters. Pearson’s 
correlation coefficient was used to assess the correlation 
between gene expression levels. The prognostic value of 
EMT-related genes was studied by dividing the tumors 
into two groups, high-expressors and low-expressors, 
using the median value of each gene analyzed as a cutoff. 
The effect of individual factors on overall survival was 
compared through hazard ratios (HR) and corresponding 
95%  confidence  interval  (CI),  estimated  by  means  of 
Cox proportional hazard model. Survival analysis was 
computed by Kaplan-Meier method, and log-rank test 
was used to evaluate the differences between subgroups. 
Statistical  significance  was  claimed  for  values  ≤  0.05 
(two-sided).
Analysis of publicly available transcriptional 
profiles
In order to assess the role of EMT drivers in 
HNSCC, a series of 11 independent datasets, deposited in 
the Oncomine (www.oncomine.com) or in the EBI Array 
express database (www.ebi.ac.uk/arrayexpress), were 
interrogated for the expression of TWIST1, TWIST2, 
SNAI1, SNAI2, E-cadherin, N-Cadherin and Vimentin. 
The  probe-level  raw  data  (.CEL  files  from Affymetrix 
chips) were imported into BRB-ArrayTools 3.7 software 
package (http://linus.nci.nih.gov/BRB-ArrayTools.html) 
that allowed to compute probeset summaries using the 
gcrma method, to apply a log2 transformation to the 
signal intensities and to normalize arrays using the median 
normalization over entire array method. Gene expression 
data were then extracted using the dedicated plug-in 
utility and analyzed as described in the statistical analysis 
section. 
When more than one probe set matched a given gene, 
the one with the highest variance was selected. Pearson’s 
correlation coefficient was used to assess the correlation 
between gene expression levels.
Only 1 out of the 11 datasets available included 
TWIST2 probe sets and provided survival data [28]. This 
dataset (Dataset XI in Supplementary Table 1) was then 
interrogated to assess the impact of TWIST2 expression 
on HNSCC aggressiveness by Kaplan-Meier method.
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